STOCK TITAN

[8-K] Picard Medical, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Picard Medical, Inc. filed a Form 8-K stating it furnished a press release discussing the volatility of its stock price. The press release is included as Exhibit 99.1 and dated October 24, 2025.

The company’s common stock trades on the NYSE American under the symbol PMI. No financial results or transactions are described in this filing.

Picard Medical, Inc. ha depositato una Form 8-K dichiarando di aver fornito un comunicato stampa che discute della volatilità del prezzo delle sue azioni. Il comunicato stampa è incluso come Exhibit 99.1 ed è datato 24 ottobre 2025.

Le azioni ordinarie della società sono negoziate sul NYSE American con il simbolo PMI. In questa presentazione non sono descritti risultati finanziari né transazioni.

Picard Medical, Inc. presentó un Formulario 8-K indicando que proporcionó un comunicado de prensa que discute la volatilidad del precio de sus acciones. El comunicado de prensa se incluye como Exhibit 99.1 y data del 24 de octubre de 2025.

Las acciones ordinarias de la empresa cotizan en el NYSE American bajo el símbolo PMI. No se describen resultados financieros ni transacciones en este archivo.

Picard Medical, Inc.는 주가의 변동성에 대해 보도자료를 제공했다는 내용의 Form 8-K를 제출했습니다. 그 보도자료는 Exhibit 99.1로 포함되어 있으며 2025년 10월 24일자입니다.

회사의 보통주는 PMI 기호로 NYSE American에서 거래됩니다. 본 제출서에는 재무 결과나 거래가 설명되어 있지 않습니다.

Picard Medical, Inc. a déposé un formulaire 8-K indiquant avoir fourni un communiqué de presse évoquant la volatilité du cours de ses actions. Le communiqué de presse est inclus sous Exhibit 99.1 et daté du 24 octobre 2025.

Les actions ordinaires de la société se négocient sur le NYSE American sous le symbole PMI. Aucun résultat financier ni transaction n'est décrit dans ce dossier.

Picard Medical, Inc. hat ein Form 8-K eingereicht, in dem bekannt wird, dass eine Pressemitteilung zur Volatilität des Aktienkurses bereitgestellt wurde. Die Pressemitteilung ist als Exhibit 99.1 enthalten und datiert auf den 24. Oktober 2025.

Die Stammaktien des Unternehmens werden an der NYSE American unter dem Symbol PMI gehandelt. In diesem Einreichungsvorgang werden keine finanziellen Ergebnisse oder Transaktionen beschrieben.

Picard Medical, Inc. قدمت نموذج 8-K يذكر أنها وفرت بيانًا صحفيًا يناقش تقلب سعر سهمها. البيان الصحفي مرفق كـ Exhibit 99.1 ومؤرخ في 24 أكتوبر 2025.

تداول أسهم الشركة العادية في بورصة NYSE American تحت الرمز PMI. لا يتم وصف أي نتائج مالية أو معاملات في هذا الملف.

Positive
  • None.
Negative
  • None.

Picard Medical, Inc. ha depositato una Form 8-K dichiarando di aver fornito un comunicato stampa che discute della volatilità del prezzo delle sue azioni. Il comunicato stampa è incluso come Exhibit 99.1 ed è datato 24 ottobre 2025.

Le azioni ordinarie della società sono negoziate sul NYSE American con il simbolo PMI. In questa presentazione non sono descritti risultati finanziari né transazioni.

Picard Medical, Inc. presentó un Formulario 8-K indicando que proporcionó un comunicado de prensa que discute la volatilidad del precio de sus acciones. El comunicado de prensa se incluye como Exhibit 99.1 y data del 24 de octubre de 2025.

Las acciones ordinarias de la empresa cotizan en el NYSE American bajo el símbolo PMI. No se describen resultados financieros ni transacciones en este archivo.

Picard Medical, Inc.는 주가의 변동성에 대해 보도자료를 제공했다는 내용의 Form 8-K를 제출했습니다. 그 보도자료는 Exhibit 99.1로 포함되어 있으며 2025년 10월 24일자입니다.

회사의 보통주는 PMI 기호로 NYSE American에서 거래됩니다. 본 제출서에는 재무 결과나 거래가 설명되어 있지 않습니다.

Picard Medical, Inc. a déposé un formulaire 8-K indiquant avoir fourni un communiqué de presse évoquant la volatilité du cours de ses actions. Le communiqué de presse est inclus sous Exhibit 99.1 et daté du 24 octobre 2025.

Les actions ordinaires de la société se négocient sur le NYSE American sous le symbole PMI. Aucun résultat financier ni transaction n'est décrit dans ce dossier.

Picard Medical, Inc. hat ein Form 8-K eingereicht, in dem bekannt wird, dass eine Pressemitteilung zur Volatilität des Aktienkurses bereitgestellt wurde. Die Pressemitteilung ist als Exhibit 99.1 enthalten und datiert auf den 24. Oktober 2025.

Die Stammaktien des Unternehmens werden an der NYSE American unter dem Symbol PMI gehandelt. In diesem Einreichungsvorgang werden keine finanziellen Ergebnisse oder Transaktionen beschrieben.

Picard Medical, Inc. قدمت نموذج 8-K يذكر أنها وفرت بيانًا صحفيًا يناقش تقلب سعر سهمها. البيان الصحفي مرفق كـ Exhibit 99.1 ومؤرخ في 24 أكتوبر 2025.

تداول أسهم الشركة العادية في بورصة NYSE American تحت الرمز PMI. لا يتم وصف أي نتائج مالية أو معاملات في هذا الملف.

Picard Medical, Inc. 提交了 Form 8-K,声明其提供了一则新闻稿,讨论其股价的波动性。该新闻稿作为 Exhibit 99.1 收录,日期为 2025 年 10 月 24 日。

该公司普通股在 NYSE American 交易,代码为 PMI。在本次备案中未描述任何财务业绩或交易。

false 0002030617 0002030617 2025-10-24 2025-10-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): October 24, 2025

 

Picard Medical, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-42801   86-3212894

(State or other jurisdiction

of incorporation)

  (Commission
File Number)
 

(IRS Employer

Identification No.)

 

1992 E Silverlake
Tucson AZ, 85713
(Address of principal executive offices, including zip code)

 

Registrant’s telephone number, including area code: (520) 545-1234

 

Not Applicable
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   PMI   The NYSE American, LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 

 

 

 

Item 7.01.Regulation FD Disclosure.

 

On October 24, 2025, Picard Medical, Inc. issued a press release discussing the volatility of its stock price. A copy of the press release is furnished as Exhibit 99.1 and incorporated by reference herein.

 

Item 9.01.Financial Statements and Exhibits.

 

(d) Exhibits

 

The following exhibits are being filed herewith:

 

Exhibit No.   Description
99.1   Picard Medical, Inc. Press Release dated October 24, 2025
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 1 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Picard Medical, Inc.
 
By: /s/ Patrick NJ Schnegelsberg  
  Name: Patrick NJ Schnegelsberg  
  Title: Chief Executive Officer  

 

Dated: October 24, 2025

 

 2 

FAQ

What did Picard Medical (PMI) report in its 8-K?

The company furnished a press release discussing the volatility of its stock price and attached it as Exhibit 99.1.

What is Exhibit 99.1 in PMI’s filing?

It is the press release dated October 24, 2025 that discusses the company’s recent stock price volatility.

Does the 8-K include financial results or new transactions?

No. The filing describes the press release about stock price volatility and includes it as Exhibit 99.1.

Where does PMI’s stock trade and under what symbol?

Picard Medical’s common stock trades on the NYSE American under the symbol PMI.

Who signed the 8-K for Picard Medical?

The filing was signed by Patrick NJ Schnegelsberg, Chief Executive Officer.

When was the press release issued?

The press release was issued on October 24, 2025.
Picard Medical, Inc.

NYSE:PMI

PMI Rankings

PMI Latest News

PMI Latest SEC Filings

PMI Stock Data

298.49M
4.25M
65.76%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
TUCSON